Key result
Five-year cancer survival is linked to a >50% probability of having at least one NCD comorbidity.
Why the study?
Noncommunicable disease comorbidities are common in cancer patients, but few studies have mapped their occurrence across cancer types using detailed national data.
Cohort (n=221,264)
Yes
There is a substantial burden of noncommunicable disease comorbidities, particularly cardiovascular disease, among cancer patients at and after diagnosis.
Warrants routine cardio-oncology assessment at cancer diagnosis; extends evidence of persistent NCD burden in long-term survivors.
Noncommunicable disease (NCD) comorbidities are common in cancer patients due to shared risk factors, but few studies have mapped their occurrence across cancer types using detailed national data. In this nationwide cohort study, we used data from Norwegian mandatory health registries to comprehensively describe NCD comorbidities at and after cancer diagnosis of 19 cancers. We included 269,956 adults registered with a first cancer in the Cancer Registry of Norway 2009-2019. Comorbidities included second cancers, cardiovascular diseases (CVDs), chronic obstructive pulmonary disease, diabetes and mental health disorders (MDs). We used intersection diagrams to examine NCD comorbidity patterns at first cancer diagnosis, and multi-state models to estimate five-year post-cancer probabilities of NCD comorbidities and death. We also provide a publicly available online application [https://ncdapp.onrender.com/] with additional results and details. Comorbidity prevalence at cancer diagnosis ranged from 35% (skin cancer) to 83% (lung cancer). CVD was most prevalent, usually co-occurring with MDs or diabetes. Lowest prevalences were found for younger patients and women. Conditioning on surviving five years, comorbidity probability exceeded 50% in all sites. Our findings show substantial comorbidity burden in cancer patients, varying by cancer site, age, and sex. Knowledge of these patterns could improve NCD prevention, treatment and surveillance.
No takes yet. Share an insight, caveat, or question.
Lergenmuller et al. (2026) conducted a cohort in Adults (≥18 years) diagnosed with first cancer at sites associated with lifestyle factors in Norway between 2009 and 2019 (n=221,264). At cancer diagnosis, NCD comorbidity prevalence ranged from 35.2% to 83.4%, and conditioning on surviving five years post cancer diagnosis, the probability of having at least one NCD comorbidity exceeded 50% for all cancer sites.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: